'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: The EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry

Europace

Volumn 18, Issue 5, 2016, Pages 648-657

  Boriani, Giuseppe ^a,b   Laroche, Cecile ^c   Diemberger, Igor ^a   Fantecchi, Elisa ^a,b   Popescu, Mircea Ioachim ^d   Rasmussen, Lars Hvilsted ^e   Dan, Gheorghe Andrei ^f   Kalarus, Zbigniew ^g   Tavazzi, Luigi ^h   Maggioni, Aldo P ^c,i   Lip, Gregory Y H ^e,j  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c European Society of Cardiology   (France)

^d Pharmacy Oradea   (Romania)

^e AALBORG UNIVERSITY   (Denmark)

^f CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^g MEDICAL UNIVERSITY OF SILESIA   (Poland)

^h MARIA CECILIA HOSPITAL   (Italy)

ⁱ ANMCO RESEARCH CENTER   (Italy)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Atrial fibrillation; Mortality; Prognosis; Registry; Stroke

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; EUROPE; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON PAROXYSMAL ATRIAL FIBRILLATION; OUTCOME ASSESSMENT; PAROXYSMAL ATRIAL FIBRILLATION; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; REGISTER; RESTRICTIVE CARDIOMYOPATHY; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; ATRIAL FIBRILLATION; CAUSE OF DEATH; CLASSIFICATION; CLINICAL TRIAL; ISCHEMIC ATTACK, TRANSIENT; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PILOT STUDY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CATHETER ABLATION; CAUSE OF DEATH; COMORBIDITY; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISCHEMIC ATTACK, TRANSIENT; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK FACTORS; STROKE; THROMBOEMBOLISM;

EID: 84975226481     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv390     Document Type: Article

References (20)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
2. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000;35: 183-7.
3. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVEWsubstudy. J Am Coll Cardiol 2007;50:2156-61.
4. Lip GY, Frison L, Grind M, SPORTIF Investigators. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. J Intern Med 2008;264:50-61.
5. Al-Khatib SM, Thomas L, Wallentin L, Lopes RD, Gersh B, Garcia D et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 2013;34:2464-71.
6. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirintreated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281-8.
7. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF trial. Eur Heart J 2015;36:288-96.
8. Boriani G, Cimaglia P, Fantecchi E, Mantovani V, Ziacchi M, Valzania C et al. Nonvalvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. J Cardiovasc Med (Hagerstown) 2015; 16:491-6.
9. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383:955-62.
10. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16:308-19.
11. Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH et al. 'Real-world' antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am J Med 2014;127:519-29.e1
12. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF pilot registry). Eur Heart J 2014;35:3365-76.
13. Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on atrial fibrillation. Europace 2015;17:24-31.
14. Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2015;17:194-206.
15. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH et al. Asymptomatic atrial fibrillation: clinical correlates, management and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509-18.e2.
16. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 2013;167:2682-7.
17. Boriani G, Diemberger I, Ziacchi M, Valzania C, Gardini B, Cimaglia P et al. AF burden is important-fact or fiction? Int J Clin Pract 2014;68:444-52.
18. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M et al. Device-detected atrial fibrillation and risk for stroke: an analysis of .10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014;35: 508-16.
19. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG et al. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008;29:915-22.
20. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146: 857-67.